Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
作者： M R Cooper , O R McIntyre , K J Propert , S Kochwa , K Anderson
DOI: 10.1200/JCO.1986.4.9.1331
关键词: Multiple myeloma 、 Cyclophosphamide 、 Cytopenia 、 Oncology 、 Melphalan 、 Carmustine 、 Regimen 、 Medicine 、 Doxorubicin 、 Pharmacology 、 Prednisone 、 Internal medicine
摘要: Four intravenous (IV) alkylating agent regimens were tested in 615 previously untreated patients with multiple myeloma. Patients randomized to receive melphalan, cyclophosphamide, and carmustine combination (MCBP), sequentially (Seq-MCBP), or doxorubicin (MCBPA). The fourth group received IV melphalan (MP) as the only agent. All groups a tapering dose of prednisone. Toxicity was similar for all although nadir cytopenia reached more quickly regime including only. Response measured by reduction myeloma protein other parameters four treatments. Survival significantly poorer receiving agents sequence. survival high tumor cell load who azotemic better treated MP MCBP. In view simplicity probable cost savings attached single-agent treatment, melphalan/prednisone regimen ...
sci-hub.se 参考文章(15)
Kyle Ra, Multiple myeloma: review of 869 cases. Mayo Clinic Proceedings. ,vol. 50, pp. 29- 40 ,(1975)
G Merlini, JG Waldenstrom, SD Jayakar, A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients Blood. ,vol. 55, pp. 1011- 1019 ,(1980) , 10.1182/BLOOD.V55.6.1011.1011
JB Harley, TF Pajak, OR McIntyre, S Kochwa, MR Cooper, M Coleman, J Cuttner, Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood. ,vol. 54, pp. 13- 22 ,(1979) , 10.1182/BLOOD.V54.1.13.13
S Pavlovsky, J Saslavsky, M Tezanos Pinto, L Palmer, M Curuchet, J M Lein, G Garay, M Dragosky, E Quiroga-Micheo, A B Huberman, A randomized trial of melphalan and prednisone versus melphalan, prednisone, cyclophosphamide, MeCCNU, and vincristine in untreated multiple myeloma. Journal of Clinical Oncology. ,vol. 2, pp. 836- 840 ,(1984) , 10.1200/JCO.1984.2.7.836
Daniel E. Bergsagel, Mouse Myeloma Archives of Internal Medicine. ,vol. 135, pp. 109- 113 ,(1975) , 10.1001/ARCHINTE.1975.00330010111014
Delvyn C. Case, Burton J. Lee, Bayard D. Clarkson, Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol The American Journal of Medicine. ,vol. 63, pp. 897- 903 ,(1977) , 10.1016/0002-9343(77)90543-5
Brian G. M. Durie, Sydney E. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer. ,vol. 36, pp. 842- 854 ,(1975) , 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
Gibbons G. Cornwell, Thomas F. Pajak, Shaul Kochwa, O. Ross McIntyre, Linda P. Glowienka, Kurt Brunner, Sameer Rafla, Richard T. Silver, M. Robert Cooper, Edward Henderson, Robert A. Kyle, Farid I. Haurani, Janet Cuttner, Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience Cancer. ,vol. 50, pp. 1669- 1675 ,(1982) , 10.1002/1097-0142(19821101)50:9<1669::AID-CNCR2820500902>3.0.CO;2-N
Daniel E. Bergsagel, Alan J. Bailey, G. Ross Langley, R. Neil MacDonald, David F. White, Anthony B. Miller, The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia New England Journal of Medicine. ,vol. 301, pp. 743- 748 ,(1979) , 10.1056/NEJM197910043011402
Giovanni Costa, Ralph L Engle, Albert Schilling, Paul Carbone, Shaul Kochwa, Ralph L Nachman, Oliver Glidewell, Melphalan and prednisone: An effective combination for the treatment of multiple myeloma The American Journal of Medicine. ,vol. 54, pp. 589- 599 ,(1973) , 10.1016/0002-9343(73)90116-2